Skip to main content
DIACEUTICS PLC logo

DIACEUTICS PLC — Investor Relations & Filings

Ticker · DXRX ISIN · GB00BJQTGV64 LEI · 213800VEWQBB39ZB8J81 IL Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 278 across all filing types
Latest filing 2021-09-13 Regulatory Filings
Country GB United Kingdom
Listing IL DXRX

About DIACEUTICS PLC

https://www.diaceutics.com/

Diaceutics PLC is a data analytics and end-to-end services provider focused on the development and commercialization of precision medicine diagnostics. The company supports pharmaceutical and biotech clients by providing solutions to improve the diagnostic testing ecosystem, aiming to ensure patients receive the correct personalized treatment. Its primary offering is DXRX, The Diagnostic Network®, a diagnostic commercialization platform for precision medicine. DXRX facilitates collaboration among stakeholders, including laboratories and pharmaceutical companies, in a secure marketplace and provides access to real-world diagnostic testing data. This integrated platform is designed to streamline the launch and adoption of new precision medicines.

Recent filings

Filing Released Lang Actions
DXRX Platform Contract Win
Regulatory Filings Classification · 100% confidence The document is a formal announcement released via RNS (RNS Number: 4749L) on September 13, 2021. It details a significant business event: securing a contract worth over $900,000 for technology-enabled services via the DXRX platform, related to supporting the launch of a new oncology drug diagnostic test. This type of announcement, which reports on a specific, material business development (like a contract win or major operational update) and is distributed through a regulatory news service, fits best under the general 'Regulatory Filings' category (RNS) as it is not a specific financial report (10-K, IR, ER), management change (MANG), or capital event (CAP, SHA). It is a general corporate disclosure.
2021-09-13 English
Two new experts join the Diaceutics Advisory Panel
Regulatory Filings Classification · 98% confidence The document is identified by the header 'RNS Number' and contains a date (08 September 2021). The content announces the addition of two new experts to the company's Advisory Panel and discusses the DXRX platform. This type of announcement, which details operational updates, expert appointments, and strategic developments but is not a formal financial report (like 10-K or IR) or a specific regulatory filing (like DIRS or DIV), is typically distributed via regulatory news services. The footer explicitly states: 'This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange.' Since it is a general, non-mandatory announcement distributed through the RNS system but is not one of the highly specific categories (like MANG for board changes, or ER for earnings), the most appropriate general classification for a non-regulatory news service release is Regulatory Filings (RNS), which serves as the fallback for miscellaneous announcements distributed via this channel.
2021-09-08 English
PDMR Shareholding/Share Incentive Plan
Director's Dealing Classification · 99% confidence The document is a regulatory notification filed via RNS (RNS Number : 3003K) dated September 1, 2021. The content explicitly details share transactions by Persons Discharging Managerial Responsibilities (PDMRs) under Article 19(1) of Regulation (EU) No. 596/2014. This type of filing, reporting insider trades or director's dealings, directly corresponds to the 'Director's Dealing' category. The presence of 'PDMR Shareholding' in the title and the detailed tables confirming transactions by executives strongly supports the classification as DIRS.
2021-09-01 English
Notice of Investor Presentation
Regulatory Filings Classification · 99% confidence The document explicitly states it is an "Investor Presentation" and details an upcoming live presentation by the CEO and CFO relating to the Company's "Interim results for the six months ending 30 June 2021". This content—a presentation aimed at investors detailing financial results and strategy—directly matches the definition for Investor Presentation (IP). Although it mentions interim results (which could suggest an IR), the primary subject is the presentation itself, not the comprehensive report. The document is an announcement about the presentation, but the core content type being announced is the presentation material. Given the specific nature of 'Investor Presentation' (IP) versus the general 'Report Publication Announcement' (RPA), IP is the most accurate classification for the subject matter being discussed.
2021-08-31 English
PDMR Shareholding/Share Incentive Plan
Director's Dealing Classification · 100% confidence The document is a notification filed via RNS (RNS Number: 1376H) dated July 30, 2021. The content explicitly details share purchases and subsequent share option grants/awards made to two Persons Discharging Managerial Responsibilities (PDMRs), Susanne Munksted and Damian Thornton, under the company's Share Incentive Plan (SIP). This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the definition of 'Director's Dealing'. The presence of the regulatory header 'Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014' confirms this is an insider transaction disclosure. Therefore, the correct classification is DIRS.
2021-07-30 English
Trading Update
Earnings Release Classification · 100% confidence The document is a brief announcement released via RNS (Regulatory News Service) on July 8, 2021. It provides a 'Trading update for the six months ended 30 June 2021' (H1 2021), detailing preliminary revenue figures and cash position, and notes that the full interim results will be announced later (September 14, 2021). Since it contains key financial highlights for a specific period (six months) but is not the comprehensive report itself, it aligns best with the Earnings Release (ER) definition. However, because it is a regulatory announcement (RNS) that precedes the full Interim Report (IR), and given its brevity and format as a market update, it strongly resembles an Earnings Release (ER) which typically provides key highlights before the full filing. The presence of the RNS header and the explicit mention of 'Notice of Results' for the full interim report confirms this is an early announcement of results, fitting the ER category. H1 2021
2021-07-08 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.